Automation Scientist -GSK-USA-Upper Providence, Pennsylvania

A biosimilar protein that can be used to treat neutropenia (a side effect of cancer chemotherapy) is to be developed by Apotex of Canada in collaboration with Intas Biopharmaceuticals Limited (IBPL) of India.

Neukine, a recombinant granulocyte colony stimulating factor (G-CSF) is already manufactured and marketed in India and other countries by IBPL. Kwizda Pharma of Austria had been working with IBPL to develop G-CSF for the European market for some time. Effective immediately, Kwizda Pharma has transferred all of its rights in IBPL's G-CSF to Apotex. Apotex and IBPL have concurrently agreed to extend the collaboration to development of G-CSF for North America (US and Canada).